Towards Healthcare
Dengue Vaccine Market to Lead USD 2297.33 Mn by 2035

Dengue Vaccine Market 2025 Revenue and Future Expansion

Market insights predict, the dengue vaccine industry is expected to grow from USD 751.01 million in 2025 to USD 2297.33 million by 2035, driven by a CAGR of 11.74%. The dengue vaccine market is growing due to a rise in government initiatives to promote dengue vaccination campaigns. North America dominates the market due to a strong presence of the pharmaceutical industry, which comprises a number of key players majorly involved in clinical trials and collaborative efforts.

Content

  • Last Updated: 06 November 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

Talk to us
FAQ's

The dengue vaccine market is worth USD 839.14 million in 2026, and by 2035, it is forecasted to hit USD 2297.33 million, registering a CAGR of 11.74% over the decade.

North America is currently leading the dengue vaccine market due to rising research in developing recombinant vaccines.

The dengue vaccine market comprises five segments type, route of administration, end users, distribution channel, and region.

Some key players include Teva Pharmaceutical Industries, Ltd., Sanofi, GSK plc, BIO-MED, etc.

Key trends include rising dengue cases and the use of biotechnology to develop recombinant vaccines.

Children and teenagers aged 9 to 16 who reside in dengue-endemic areas and have laboratory proof of a prior dengue virus infection are eligible for the Dengvaxia dengue vaccine.
Any Questions